exRNAdisease

Entry Detail

---



General Information

Database ID: exR0269387 RNA Name: hsa-miR-139-5p RNA Type: miRNA Chromosome: chr11 Starnd: - Coordinate: Start Site(bp): 72615102 End Site(bp): 72615124 External Links: hsa-miR-139-5p

Disease Information

Disease Name: Multiple Sclerosis Disease Category: Nervous System Diseases MeSH ID: D009103 Type: Diseases Category/Nervous System Diseases Alias: Sclerosis, Multiple//Sclerosis, Disseminated//Disseminated Sclerosis//MS (Multiple Sclerosis)//Multiple Sclerosis, Acute Fulminating

Expression Detail

GEO ID: GSE140106 Description: Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment Experimental Design: Fingolimod treatment Case Disease Type: Multiple Sclerosis Case Disease SubType: NA Case Sample: Fingolimod treated Multiple Sclerosis Control Sample: Untreated Number of Case: 27 Number of Control: 27 Number of Samples: 54

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AP3M1 chr10 74120255 74151063 - ARIH1 chr15 72474330 72602987 + FBN2 chr5 128257909 128659185 - ISG20L2 chr1 156721891 156728799 - ITGA3 chr17 50055968 50090481 + JPT2 chr16 1678256 1702280 + KLHL28 chr14 44924319 45042322 - LRP8 chr1 53242364 53328469 - MKLN1 chr7 131110096 131496632 + SLC26A2 chr5 149960758 149993455 + SLC31A1 chr9 113221544 113264492 + TGOLN2 chr2 85318020 85328296 - TPM4 chr19 16067021 16103002 + WIPF2 chr17 40219304 40284136 + YWHAB chr20 44885702 44908532 + miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC068768.1 chr12 123262060 123262402 + AC084082.1 chr8 66112667 66126632 + AL132655.1 chr20 58833809 58836529 - NEAT1 chr11 65422774 65445540 + NUTM2A-AS1 chr10 87201647 87342612 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE140106 Sample Source: Blood Source Fraction: Exosome Platform: GPL11154 Method: NGS Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1907 Sample treatment protocol: Exosomes were isolated from 1 mL RNase A (37 °C for 10 min; 100 ng/ml; Qiagen, Australia) treated serum, by size exclusion chromatography (qEV iZONE Science). RNA Extract protocol: Serum exosomes were processed for RNA extraction using the Plasma/Serum Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) according to the manufacturer's protocol. RNA library preparation protocol: Exosome RNA sequencing libraries were then constructed using the NEBNext Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) according to the manufacturer's instructions.

Reference

PMID: 31721043 Title: Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment Author: Ebrahimkhani S, Beadnall HN, Wang C, Suter CM, Barnett MH, Buckland ME, Vafaee F Journal: Mol Neurobiol. 2020 Feb;57(2):1245-1258. Description: we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy.